Fig. 2From: Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patientsAssociation between TIMs infiltration and benefit from gemcitabine-based adjuvant chemotherapy (ACT). (a) Patients without ACT in the discovery set. (b) Patients with ACT in the discovery set. (c) Patients without ACT in the validation set. (d) Patients with ACT in the validation set. P value was calculated by log-rank testBack to article page